WE Life Sciences

Q1 2023

Wallonie Entreprendre


Wallonie
Entreprendre
Life Sciences

Life Sciences: big success comes from small companies

If COVID-19 has shown us one thing, it's that small companies are the key drivers of innovation in life sciences today.

Wallonie Entreprendre Life Sciences

Wallonia has a unique position within the life sciences

Over 180 **small and medium-sized life sciences companies.**

A solid network of **renowned universities** and research institutes.

Strong track record in life sciences, as leading industry players have acquired several Walloon life sciences companies in recent years.

Home to some of **Belgium's most promising startups**, including Univercells, Imcyse, Novadip Biosciences, Epics Therapeutics, PDC Line Pharma, iStar Medical ...

Key research, production, and logistic activities of **global companies** like GSK Vaccines, Baxter, Johnson & Johnson, Abbvie, Takeda, UCB, IBA, Zoetis and Catalent.

Wallonie Entreprendre Life Sciences

Wallonia’s life science success is under pressure

Today more than ever, Walloon companies are facing **intense competition in the global market,** with long-term initiatives and large amounts of funding available in Asia, US and other countries in Europe.

Wallonie Entreprendre Life Sciences

We choose to invest in ‘local heroes’

Virginie Cartage
CFO **Novadip Biosciences**

We fund life sciences entrepreneurs who leverage their innovation to build a sustainable and equitable global economy **with roots in Wallonia.**

Wallonie Entreprendre Life Sciences

What we bring to the table

1. Early & patient investment
2. Diversification
3. Heart & Soul

Wallonie Entreprendre Life Sciences

1. Early and patient investment

We are comfortable investing in the most promising very early-stage companies and can act with a long-term view – longer than the average VC.

We are not afraid to go to places where few people have been before.

Wallonie Entreprendre Life Sciences

2. Diversification: stage, technology, team

We focus on diversity and cross-fertilization in its broadest sense.

We invest in life sciences companies at diverse stages of development, across a broad range of technologies and disease areas, and with a global vision.

Wallonie Entreprendre Life Sciences

3. Heart & Soul: together to the top

We are committed to making each of our companies successful.

We don't limit ourselves to providing funding and advice to our companies.

We are known for personally guiding them on the challenging journey of turning innovation into a successful business.

Wallonie Entreprendre Life Sciences

Our Team
Caroline Thielen, PhD

Investment Manager
caroline.thielen@wallonie-entreprendre.be | +32 498 706222

Board member

epics THERAPEUTICS

EyeD Pharma
Delivery of VISION CARE

Cellaïon

KiOmed PHARMA

Dendrogenix

ExeVir

Other companies

UniD Manufacturing
Your INDUSTRIAL PARTNER for drug release in micro dimensions

iSTAR MEDICAL

PDC*line pharma
ADVANCED CANCER VACCINES

Wishbone

D-tek

miracor medical

Wallonie Entreprendre Life Sciences

Our Team
Christina Franssen, PhD

Investment Manager
christina.franssen@wallonie-entreprendre.be | +32 474 397399

Board member

Imcyse
specific active immunotherapeutics

NOVADIP

exothera

Ncardia
Stem cell experts

NeuVasQ
BIOTECHNOLOGIES

Other companies

Univercells
Biologics for all

Synergia Medical

THERATRAME
Discover new therapies

EsoBiotec

Wallonie Entreprendre
Life Sciences

Our Team
Gery Lefebvre, MBA

Investment Manager
gery.lefebvre@wallonie-entreprendre.be | +32 496 211340

Board member

- minoryx therapeutics
- QUALITY ASSISTANCE Contract Research Organisation
- KitoZyme Our technologies for Health Your success!
- IDDI PASSION. SCIENCE. EXPERIENCE.
- BiOkuris
- OSIMIS IMAGING · RE-WIRED

Other companies

- iba
- Hyloris PHARMACEUTICALS
- OncoDNA THE CANCER THERANOSTIC COMPANY
- CluePoints
- MAN & SCIENCE
- Intressa VASCULAR

Our Team
Sophie Sauvage, MBA

Investment Manager
sophie.sauvage@wallonie-entreprendre.be | +32 473 823094

Board member

gabi SMARTCARE

The Akkermansia Company™

AXINESIS ADVANCING REHABILITATION

ASEPTIC TECHNOLOGIES

SPINOVIT .COM

NEWTON BIOCAPITAL

Other companies

LiveDrop

neuroClues biomarkers in a blink

AARDEX GROUP

CERHUM Ceramics for Humans

MYOCENE

Wallonie Entreprendre Life Sciences

Our Partners



Wallonie Entreprendre Life Sciences

Wallonie Entreprendre Life Sciences

#chooselife

About WE Life Sciences

€ 312 M

Total AUM
at the end of Q1 23

64

Active Portfolio Companies
at the end of Q1 23

>4.000

Direct Jobs
in active portfolio

€ +222 M (+1M)

Cumulative ROI
(Q1 23)

Wallonie Entreprendre Life Sciences

About WE Life Sciences

Activity Types



Asset Classes



Financial Assets



Wallonie Entreprendre Life Sciences

Track Record

M&A

ogeda

Sold to **Astellas** for 800 M € in 2017
Multiple 22,8x (up to 24,3x)

diagenode
A Hologic Company

Sold to **Hologic** for 130 M € in 2021
Multiple 4,0x

ASEPTIC TECHNOLOGIES

Partly sold to **Skan** in 2022
Multiple 2,8x

syndesi therapeutics

Sold to **Abbvie** for up to 1 B $ in 2022
Multiple 5,2x (up to 29,7x)

UTERON PHARMA

Sold to **Watson Pharma (now AbbVie)** for 305 M $ in 2013
Rights sold to **Mithra Pharma** in 2015
Multiple 3,7x

Ncardia
Stem cell experts

Partly sold to **Kiniciti** in 2021
Multiple 1,8x

IPO

iTEOS THERAPEUTICS

Nasdaq in 2020
201 M $ raised at IPO

Celyad Oncology

Euronext in 2013 & **Nasdaq** in 2015
115 M € raised at IPOs

Nyxoah
The path to restful nights

Euronext in 2020 & **Nasdaq** in 2021
167 M € raised at IPOs

mithra
Women's Health

Euronext in 2015
79 M € raised at IPO

Wallonie Entreprendre Life Sciences

News flow, Q1 2023

April 6 **Myocene** raises € 2 Million to prepare the market access of its measurement technology of human muscle fatigue dedicated to high-level athletes.

March 24 **Celyad Oncology** appoints Georges Rawadi as its new CEO

March 15 **iSTAR Medical** initiates international STAR-VI trial for the use of MINIject in conjunction with cataract surgery

March 14 **IBA (Ion Beam Applications S.A.)**, the world leader in particle accelerator technology wants to hire 100 new employees during the first half of 2023.

March 6 **Nyxoah** Announces Achievement of Key Clinical and Regulatory Milestones. The company has completed all 115 implants in its DREAM U.S. pivotal study, submitted the first module in the modular PMA submission and implanted the first patient in the ACCCESS U.S. pivotal study.

March 3 **Mithra** announces positive topline safety results from the Phase 3 Donesta® pivotal E4 COMFORT clinical trial in the United States and Canada.

March 1 **Imcyse** Announces Completion of Enrollment in Phase 2 IMPACT Trial of IMCY-0098 for Type 1 Diabetes

February 15 Gedeon Richter Plc. and **Mithra Pharmaceuticals** sign a licence agreement for the commercialisation of Donesta®, a novel product candidate for the treatment of post-menopausal symptoms.

February 10 **Novadip Biosciences** is now enrolling participants for its Ph 1b/2a trial evaluating NVD-003 for the treatment for congenital pseudarthrosis of the tibia (CPT).

January 26 **Aseptic Technologies** and Skan AG are expanding by building a 2500m^2 extension next to their existing building in Belgium. And on top of it, 460 solar panels to help meet their ESG goals.

Wallonie Entreprendre Life Sciences

In Our Portfolio

Univercells
Biologics for all

investors@univercells.com
www. univercells.com

Corporate

Founded in 2013

Global company with **HQ in Belgium**

Funds raised since inception: 253 M € in total between equity and non-dilutive funding

Univercells Management: Hugues Bultot (CEO), Vincent Vanderborght (CFO), David Louvet (COO), Kate Antrobus (CIO)

Affiliate CEO's: Mathias Garny (Univercells Technologies); Thibault Jonckheere (Exothera); José Castillo (Quantoom); Hala Audi (Unizima); David Louvet (RLM Consulting)

Business

Univercells Group is a campus of startups and scaleups, consisting of five affiliates – Univercells Technologies, Exothera, Quantoom, Unizima and RLM Consulting – under the parent company, Univercells SA.

Each affiliate provides a different solution to the same problem: how to meet the global demand for bioproduction through technology and services. These synergistic solutions ensure that when game-changing vaccines or therapies exist, they are accessible to those that need them.

Technology

- Univercells Technologies:
  - 20 M € Additional investment by Gamma Biosciences (reaching 54% ownership)
  - scale-X™ bioreactor portfolio: 180+ installed base; first GMP runs
  - NevoLine™ platform
- Exothera:
  - 2 new GMP certified production facilities; 15 projects
- Quantoom Biosciences:
  - Delivery of first RNA production equipment; commercialization by end 2022

Milestones

- EIB venture debt of 50 M €
- Redesigned Group organization post carve-out in 2020; repositioned Quantoom in RNA
- Positioned in Global Health circles thanks to first project in Dakar
- Acquisition of SynHelix (2021)
- Acquisition of RLM Consulting (2022)
- Collaboration agreement with Afrigen Biologics on RNA Hub
- Gamma Biosciences option exercise (2022)
- Raised 44 M € in Series-D financing (2022)
- US expansion (2023)

Wallonie Entreprendre Life Sciences

In Our Portfolio

Ncardia
Stem cell experts

cellistic

Contact: Stefan Braam (CEO)
Stefan.braam@ncardia.com
www.ncardia.com

Corporate

Founded in 2014
Global company with headquarter in Belgium and subsidiaries in Netherlands and USA
Currently 60+ employees, continuous expansion
CEO Stefan Braam

Business

Ncardia:
Ncardia provides specialized screening and analytical services using iPSC derived human tissues in vitro to derive novel insights for gene therapy, biologic and small molecule drug candidates. By bringing specific human biology into the lab, we help therapeutic developers to get complex therapies get to market faster, by performing novel analyses in vitro, that greatly enhance the probability of in vivo success.

Cellistic :
Cellistic is building world-class robust and scalable allogeneic iPSC-based immune cell therapy development and manufacturing platforms that enable cell therapies to achieve their full potential in improving human health.

Technology

Area of interest: applications of stem cell derived cells in drug discovery and cell therapy
Services description:

- **Ncardia:** Drug discovery services using Ncardia healthy and diseased cellular models
- **Cellistic:** IPSC cell therapy contract development and manufacturing services

Milestones

- **€60M raise with private equity partner Kiniciti in Nov 2021**
- **Launch of Cellistic in April 2022**
- **Cellistic announces partnership with Quell therapeutics for the development of iPSC Treg therapeutics in May 2022**

In Our Portfolio

QUALITY ASSISTANCE
Contract Research Organisation

www.quality-assistance.com

Corporate

Founded in 1982
CRO (Contract Research Organisation)
Private, independent limited company
CEO Philippe Draux
COO Nathalie Draux
Revenues 2021: EUR 27 million
EBITDA/CA 2021: 32%
Headcount 2021: 203 FTE

Business

All the analytical services required by **EMA** and **FDA** regulations for the **development** and **marketing** of **innovative human medicinal products**

- **New Chemical Entities**
  - Peptides
  - Oligonucleotides
- **Biologics**
  - Antibody-Drug Conjugates
  - Monoclonal antibodies
  - Proteins
- **Nanomedicine Products**
- **Vaccines**
- **mRNA**
- **Cell and Gene Therapies**

Technology

- Mass Spectrometry
- Bioassays
- Protein Characterisation
- Molecular Biology
- Chromatography
- Bioanalysis (PK/TK/Immuno)
- Immunoassays
- Microbiology

Milestones

2021: Starting a 4th facility expansion phase in order to reach 12 000 m^2
3 facility expansion phases, reaching 6 000 m^2
GMP certified since **1984**
GLP certified since **2004**
Achieved its 2015 goal of access to **500 innovative drugs (Challenge 2015-2021)**
FDA inspected in **2019, 2014, 2010, 2003**

Wallonie Entreprendre Life Sciences

In Our Portfolio

info@asepticteh.com
www.asepticteh.com

Corporate

Founded in 2002
Belgian company with international reach, member of SKAN Group (Switzerland).
Turnover (2022): 25 M€
Management team: Patrick Balériaux (CEO)

Technology

- Aseptic filling technology (AT-Closed Vial® Technology, made of ready-to fill vials and related filling equipment)
- Aseptic fluid path: manufacturing of filling kits (AT-Filling Kit™), aseptic liquid transfer systems (AT-Port™)
- Custom injection-molding and clean manufacturing of pharmaceutical devices.

Business

Aseptic Technologies manufactures fill & finish equipment and devices for advanced pharmaceutical manufacturing. Our core expertise lays in the innovation of aseptic filling processes for biopharmaceutical products, including cell and gene therapy products.
As member of SKAN Group, we leverage technological excellence of SKAN in the isolator design, providing integrated solutions for fill & finish projects, globally.
Furthermore, we share decades of expertise in injection molding and manufacturing in cleanroom, offering customized ready-to-use assemblies for pharmaceutical processes.

Milestones

Integration with SKAN Group (2019)
First drug product approved in AT-Closed Vial® in Japan (2020)
Building expansion (2023)
500th equipment installed (2023)

In Our Portfolio

CEO: denis.dufrane@novadip.com
CFO: virginie.cartage@novadip.com
www.novadip.com

Corporate

Origin:
2013 UCL & St Luc Hospital Spin-off
Fund raising since inception : € 92M equity + non-dilutive

Team:
~40 employees
Denis Dufrane - CEO, Scientific Founder | Virginie Cartage – CFO | Eric-Paul Pâques - Chairman

Business

Develop a **new class of regenerative tissue products** that accelerate healing of large bone defects, bone non-union and spine fusion **in a single treatment**

Technology

3 categories of products derived from one unique technology platform

- **Autologous** : autologous product for large bone reconstruction at clinical stage
- **Off-The-Shelf:** allogeneic product with biological properties for common orthopedic conditions to position as a key competitor in the Graft Bone Substitute market
- **Cell-free Exosome/Matrisome:** Discovery programs targeting oncology (tumor regression) and rejuvenation

Milestones

- **Autologous:** Clinical trial in adults with bone non-union - completed (EU), **FDA pilot trial ongoing** in a rare and pediatric indication (US+EU)
- **Off-the-shelf: Two clinical trials ongoing** (EU): one in spine fusion and one in trauma (radius)
- **Cell-Free Exosome Based: In vivo** POC

In Our Portfolio

Contact Person: Denis Bedoret, CEO
info@imcyse.com
www.imcyse.com

Corporate

Spin-off from the KU Leuven
Relocated to Liège in 2012
Completed Series B financing (EUR 49m) in 2019 with extension in 2021
Team above 45 FTE

Technology

Imotope™ technology; modified peptides eliciting cytolytic T cells
Addressing **autoimmune diseases**
Pre-clinical POC in several indications achieved
Clinical POC in type 1 diabetes

Business

Develop a sustainable and diverse pipeline with strategic collaborations to accelerate the clinical development of our targets
Licensing deal (incl upfront and equity) with Pfizer in rheumatoid arthritis
Phase 2 clinical program in type 1 diabetes ongoing with promising IA data (immune signature)
Phase 1b (adaptive into phase 2a/b) in Multiple Sclerosis filed in Dec 2021

Milestones

Phase 2 clinical study in type 1 diabetes ongoing with positive IA data (immune signature) obtained in Dec 2021 and complete efficacy data expected in H2 2023

Phase 1b/2 clinical study in Multiple Sclerosis to start in H1 2022 with IA data expected in H2 2023 (ie immune signature and disease activity markers)

Additional phase ½ studies including **clinical proof of concept** in other indications (NMO, Rheumatoid Arthritis, Coeliac Disease) to be started in in 2023

Epics_logo_RGB.svg

In Our Portfolio

Fobermayr@epicstx.com
www. Epicstherapeutics.com

Corporate

EPICS Therapeutics was founded 2018
Headquarters in Gosselies, Belgium
Fund raising since inception: ~€30 M equity
Management team:
CEO Franz Obermayr
CSO Graeme Fraser

Business

EPICS is a clinical stage drug discovery and development company that pioneers the development of small molecule drugs targeting RNA modifying proteins in oncology.

Technology

EPICS has developed a pipeline of new proprietary first and best in class molecules with unique mode of actions in areas of oncology with substantial unmet medical needs.

Milestones

- EP102 is a best in class inhibitor of METTL3 with single agent activity in liquid and solid tumors and will start clinical testing in patients in 2024
- Epics recently successfully concluded a phase 1 clinical study with EP282 targeting FFAR2 in immuno-oncology and other immune related diseases.

Wallonie Entreprendre Life Sciences

In Our Portfolio

Marc Martinell (CEO); +34 93 544 14 66
www.minoryx.com

Corporate

Founded in 2011
Raised €120M
25FTEs with operations in Belgium (Brussels South Biopark) and Spain (Barcelona)
Marc Martinell (CEO), María Pascual (CRO), Arun Mistry (CMO), Hans Christian Keller (CBO)

Technology

Lead candidate: leriglitazone (PPAR gamma agonist)
In MAA for X-ALD (chronic form; AMN) in EU and Phase 2/3 for acute form (cALD) in pediatric patients
Proof of concept study completed for Friedreich's Ataxia
Orphan Drug Designation granted for X-ALD (EU & US)
License agreement with Neuraxpharm for the European rights to leriglitazone

Business

First to market opportunity in X-ALD – most advanced drug candidate worldwide
Indication expansion to Friedreich's Ataxia and other CNS diseases

Milestones

Interim results pediatric study by early 2023.
Launch US study for NDA approval path by mid 2023
EU approval by late 2023.
Aiming to become a worldwide leader in X-ALD and other orphan CNS diseases

In Our Portfolio

PDC*line pharma
ADVANCED CANCER VACCINES

Contact Person: Eric Halioua, CEO
contact@pdc-line-pharma.com
www.pdc-line-pharma.com

Corporate

Founded in 2014
Spin-off from EFS (France)
Fund raising since inception: 52M€
Last round has been led by the Asian leading VC Korean Investment Partners (KIP)
A team of 31 people
CEO: Eric Halioua

Business

Deals
Licensing deal signed with LG-Chem, for the development and commercialization of PDC*lung for lung cancer in Asia. Total deal value is 123M$ plus significant tiered royalties on net sales.

Markets
PDC*line platform can be used for the treatment of virtually all cancer patients expressing HLA-A2 – with extension possibilities to other HLAs.
Revenues potential in the range of € 3 BN to € 4.5 BN in the US and EU

Technology

Platform
New class of potent and off-the-shelf therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line)

Milestones reached

- A robust preclinical package and a first-in-human phase Ib in 9 melanoma patients
- Phase I/II trial ongoing in lung cancer in France, Belgium, Netherland, Poland and Germany on 64 patients. **Preliminary results with PDC*lung01 in monotherapy and at low dose with pembrolizumab evoke acceptable safety profile, immunological activity and promising tumor response in Non-Small Cell Lung Cancer**
- Preclinical program with neoantigens based vaccines (PDC*Neo)

Milestones

Clinical study report for phase I/II clinical trial with PDC*lung by 2024
US and Asia lung cancer study initiation in 2025/2026
Initiation of trial for a new indication in 2024
Complete new round of financing in 2023
Seeking collaborations with biopharma companies

In Our Portfolio

Contact Person: Torsten Mummembrauer
tmummenbrauer@exevir.com
Visit our Website www.exevir.com

Corporate

Spin-off from VIB
Founded in 07/2020
Raised Series A financing (EUR 42m)
Raised total of EUR 58.5 m in equity incl. loans and grants
Torsten Mummenbrauer (CEO), Fiona du Monceau (COO)

Business

Best in class opportunity SARS-COV-2 neutralising antibody

Building infectious disease pipeline

Technology

- **Unique, modular VHH platform** harnessing multi-specific antibodies for prophylaxis and treatment of bacterial and viral infectious diseases
- **2nd generation COVID-19 multi-specific antibodies:**
  - **Multiple candidates** under preclinical evaluation
  - **XVR012 - Lead candidate** targeting **S1 and S2 subunits** of the spike protein. Preclinical package
  - Focused on protecting **high-risk populations** in particular the immunocompromised and addressing **current/future variants**
- New program targeting **Dengue** with potential multispecific candidate with **triple mode of action**
- Research collaboration with **VIB- Ghent University**

Milestones

- Final preclinical package of XVR012 – in 2023
- Selection of Dengue lead candidate

In Our Portfolio

EsoBiotec

Info@esobiotec.com

Corporate

Founded in October 2020.
Located in Gosselies.
Raised over 9M€ since inception.
Cash runway into 2024.
CEO: Jean-Pierre Latere
VP of R&D: Philippe Parone

Technology

ENaBL platform for in vivo engineering of cells for production of cell therapies for both hematological malignancies and solid tumors.

ENaBL is a disruptive proprietary technology that allows manufacture of cost effective off-the-shelf products for cancer patients.

Business

In vivo production of CAR-T and TCR-T products to treat various cancers.

Milestones

Preclinical proof of concept and pre-GMP manufacturing in 2022/2023.

Wallonie Entreprendre Life Sciences

In Our Portfolio

Benoit Vanhollebeke (CSO)
https://neuvasq.com/

Corporate

Origin:
Founded in 2021 as a ULB Spin-off
Raised € 20M
Headcount:
3 employees
Benoit Vanhollebeke – CSO, Scientific Founder
Michel Allé - Chairman

Technology

Area of interest :
Pharmaceuticals restoring blood-brain barrier function in neurological disorders

Business

Milestones

In Our Portfolio

contact@dendrogenix.com
s.silvente@dendrogenix.com (CEO)
www. dendrogenix.com

Corporate

- Company creation : 2018
- Funds raised since inception : 10 M€ in Series A and 4,5 M€ non-dilutive from SPW
- Headquarters in Liège
- 20 staff members
- Stéphane SILVENTE, CEO
- Frédéric THIVET, CFO
- Nicolas CARON, CTO
- Pierre ATTALI, CMO

Business

Dendrogenix is a biopharmaceutical company based in Liège dedicated to developing **first-in-class molecules named "Dendrogenins"** to address important unmet medical needs in cancer and neurodegenerative diseases with a first therapeutic indication on hearing loss, and more specifically in presbycusis indication with Dendrogenin DX243 lead product.
The presbycusis market segment represents a real opportunity as the first targeted pathology. It is an excellent therapeutic indication to illustrate the potential of DX243 in all diseases where synapses uncoupling is involved.

Technology

The origin of the discovery of the breakthrough technology of the Dendrogenins results from functional genomics studies.
These molecules stimulate cell differentiation in the immune and nervous system and induce the growth of dendrites on dendritic cell and neuron precursors.

Milestones

2018/2019 :
- Assets acquisition from Affichem & Inserm (FR)
- Non-dilutive funding granted by SPW EER
- Implementation of the Drug discovery & Development platform
- Noshaq investment

2020/2021 :
- Scale-up and manufacturing of a GMP batch of DX243
- Fund-raising from Med-El & non-dilutive funding from SPW EER

2022 :
- Regulatory toxicology package of DX243
- Fund-raising from Noshaq, WE & Med-El
- Non-dilutive funding from SPW EER

2023 :
- Phase I in hearing loss indication

In Our Portfolio

info@theratrame.com
www.theratrame.com

Corporate

Spin off of ULIEGE - WELBIO
Seed funding 2.5M€ + 2M€ non dilutive
Francesca RAPINO, COO & co-founder
Pierre CLOSE, CSO & co-founder

Technology

Objective: Build a discovery platform to generate drug candidates for the benefit of cancer patients

Technology: Develop small molecules inhibitors targeting the tRNA epitranscriptome (tRNA modification enzymes)

Proprietary protected technologies (HTS-LTS- AI-based prediction software and hits validated for target#1

Business

Four programs in the pipeline at different stages of development
AI-based technological platform to support the programs and to optimize clinical opportunities
Solid tumors with a focus on immuno-oncology

Milestones

R&D:
1/demonstrate the druggability of target#1
2/ PoC of the THERAtRAME discovery platform

Business:
Define the business-relevant clinical indication for target#1
Initiate partnership with relevant pharma companies

Corporate objectives:
Build a dynamic team to develop the DD programs
Build an international governance strategy

In Our Portfolio

Etienne.sokal@cellaion.com
www. cellaion.com

Corporate

Origin
- Founded in 2021
- € 16 M raised funds

Management team:
Etienne Sokal, PhD, MD: CEO and CMO
Mustapha Najimi, PhD: CSO
Bruno De Keersmaeker: Head of Finance
Eric Pauly: Head of Operations & CMC
Virginie Barthel: Head of Clinical
Noelia Gordillo: Head of Medical Affairs

Business

Tissue and Organ regeneration
Current Target: Liver → ACLF
- Affecting 25k patients per year in top 5 EU countries, with a 50 to 70% short term mortality.
- **Unique positioning – no alternative treatment available.**
- First in class already in phase IIB clinical development.
- Conditional approval expected 2024

Technology

HEPASTEM® Platform: Liver & Life saving advanced therapy ; liver repair and organ regeneration
Current Positionning: Liver and systemic inflammatory diseases
Product: HepaStem®: Advanced therapy medicinal product, cell signaling technology, immune modulatory and anti-inflammatory activity; targeting fibro-inflammatory liver diseases, Acute on Chronic Liver Failure and other life threatening liver diseases.

Milestones

- Strong safety preclinical and clinical package , > 100 patients infused
- Phase IIa study completed in Acute on Chronic Liver Failure (ACLF) Positive preliminary efficacy signals
- Historical safety package in infants and children with inborn errors of metabolism
- Phase II A study completed in pre cirrhotic and cirrhotic liver diseases F3 and F4 – NASH related
- **DHELIVER:** Ongoing phase IIb (EU), Proof of Concept, in ACLF , **CSR** S1 2023 (1/3rd of patients recruited).
- Preparing development in US and China.
- Japan development in ACLF under Sagikake procedure (Japan partner to be identified)
- Pipeline indications: Acute Alcoholic Hepatitis, Acute decompensation of cirrhosis, inflamed NASH.
- 2nd generation product, genetic modifications of Hepastem®

In Our Portfolio

Contact Person: BLONDEL François
CEO (info@kitozyme.com)
www.kitozyme.com

Corporate

Founded in 2000
Spin Off ULiège
35 mio EUR = Funds raised since incorporation

Technology

BioTech - Bio-polymers:
- Chitosan
- Chitin-glucan

World leader fungal chitosan
Patents & Innovation

Business

1. Health Care
- Digestive Health
- Weight Management
- Cardiovascular

2. Agriculture
- Wine
- Plant

Milestones

2000-2012: R&D
2014: Spin-out of
KiOmed Pharma – Biomedical applications
2015: Financial Break-even
2016: Net profit
2011-2019: Sales growth of + 34% per annum



In Our Portfolio

michael@theakkermansiacompany.com
www.theakkermansiacompany.com

Corporate

Co-spin off UCLOuvain & Wageningen University
31 mio eur raised to date
Michael Oredsson CEO
Prof. Willem de Vos & Prof. Patrice Cani Co-Founders

Technology

Food supplements based on a next generation bacteria:
akkermansia muciniphila

First product launched targeting weight management with glucose control; additional health disorders soon to be covered

Business

Microbiome based food supplement products

Milestones

2019: First in **human clinical trial** on metabolic syndrome published in Nature Medicine
2021: First time a **« Novel Food »** label is granted by the European Union for a next generation bacteria; EU market authorization; US market authorization
2022: **commercial launch** in Europe
2023: additional **funding**; commercial **expansion** (in geographies and in product range); further **human data** generation

In Our Portfolio

Contact: Attila Borbath (CEO)
attila.borbath@synergiam.com
www.synergia-medical.com

Corporate

- Founded in 2014 by Atilla Borbath and Pascal Doguet.
- Management team: A. Borbath (CEO), Dan Scherrer (COO), Carole Monterrat (CFO), Anne Renaud (VP Business development), Gijs Klarenbeek (VP Clinical Affairs).
- Synergia Medical raised to-date EUR 16.8M in Series A, EUR 12.8M in Series B and EUR 5M non-dilutive (with WE as one of the main players).

Technology

- First medical device company worldwide developing an optoelectronics neurostimulator.
- This neurostimulator sends monochromatic light from an implanted rechargeable pulse generator, via optical fibres, to a photovoltaic cell implanted nearby the target site where light is transformed into electrical pulses.
- Metal-free casing & lead: can be used in MRI and hosts physiological parameters sensors for fine-tuning neurostimulation modulation.

Business

- **First market target:** drug-resistant epilepsy patients, 20M people worldwide.
- **Many other applications** can benefit from the technology: depression, migraine, sleep apnea, heart failure, etc.
- **Strong research project** financed by the Walloon Region and aiming at improving quality of life for the patients.
- **Regulatory and market access:** Europe and the USA

Milestones

- 2022: GLP preclinical study
- 2023: V&V testing
- 2024: FIH in 3 European centers
- 2024: Series C (EUR 25M)
- 2025: US and European Pivotal clinical study
- 2027: CE mark and FDA approval

In Our Portfolio

EyeD Pharma
Delivery of VISION CARE

General : info@eyedpharma.com
Investor : m.foidart@eyedpharma.com
www. eyedpharma.com

Corporate

- **Founded** in 2012
- **Funds raised since inception : 113,2 M€**
- Headquarters in **Liège**
- **~ 100** staff members
- **Mélanie Mestdagt,** CEO
- **Marc Foidart,** Executive Chairman

Business

EyeD Pharma is a pharmaceutical company dedicated to improve patient's daily lives by passionately developing **innovative healthcare products** from unmet needs to market, mainly focused on **ophthalmology**, but also allowing other applications outside our focus thanks to our disruptive technological platform and our unique expertise **in micro dimension**.

In 2019, UniD Manufacturing, a sister company of EyeD Pharma, was born, bringing together **production activities**. In parallel with its R&D and industrialisation activities, EyeD Pharma started in 2017 a **distribution activity** of medical devices (equipment and consumables) for eye surgery.

Technology

- Specialise in the development and production of ocular micro-implants
- **Innovative healthcare products** from unmet needs

Milestones

2012 – 2015 :
- Company creation and **first scientific validations**

2016 :
- Capital increase and new public grants

2017 :
- AFMPS agreement as distributor – Starting distribution business
- **Final prototype** for glaucoma implant

2018 – 2019 :
- **Bausch and Lomb exclusive distribution** in Be-Lux
- Preliminary proof of concept animal for glaucoma implant
- Capital increase
- Own industrial process development, internalisation

2021 :
- Fund-raising, new public grants and capital increase
- **CTA submission**

2022 :
- Inauguration of **new office and CDMO**
- TimoD **Clinical Phase 1 on patients**
- **GMP** agreement for the CDMO

Wallonie Entreprendre Life Sciences

In Our Portfolio

UniD Manufacturing
Your global CDMO for drug release in micro dimensions

General : info@unid-manufacturing.com
Investor : m.foidart@unid-manufacturing.com
www.unid-manufacturing.com

Corporate

Founded in 2019
Headquarters in Liège
Mélanie Mestdagt, CEO
Marc Foidart, Executive Chairman

Technology

POLYMERIC FORMULATIONS
- Biodegradable
- Non-biodegradable
- Resorbable
- Medical devices & drugs

CONTROLLED RELEASE
MICRO TECHNOLOGY

Business

UniD Manufacturing is the first global CDMO fully dedicated to micro implants.

From your ideas to the market, we are the partner who supports and endorses you through every stage of your project based on bioresorbable, biodegradable and non-biodegradable polymers, for medical devices and drugs.

We are an excellence center with a unique tailor-made in-house equipment in a GMP approved environment, and talented experts to develop and manufacture your polymeric-based formulations and your controlled release products, at micro level.

Services

- R&D and preclinical
- Clinical phases
- End-to-end support

Think big.
We'll make it really small.

Wallonie Entreprendre Life Sciences

In Our Portfolio

Contact Person:
Houtaï CHOUMANE, CEO
+32(0)4 228 80 40
contact@kiomedpharma.com
www.kiomedpharma.com

Corporate

Founded in 2014
Funds invested in innovation and development > 25M€
40+ employees
Spin-out from KitoZyme

Houtaï CHOUMANE, CEO
François BLONDEL, Founder & Executive Chairman

Business

Target market
Hyaluronic acid products' markets for **Osteoarthritis, Aesthetic medicine**, and **ophthalmology** representing >10B $

Product on the market
KiOmedine®^{Vs}One, a unique single-injection fluid implant for knee osteoarthritis

Products in development
A pipeline of 4 products in aesthetic medicine, 2 products in ophthalmology and 2 products in osteoarthritis

Technology

Unique position in ultrapure animal-free chitosan polymer:
the KiOmedine®
Area of interest: Regenerative medicine (Osteoarthritis, Aesthetic medicine, and ophthalmology)
Products description
Class III injectable implants

Milestones

GLOBAL TARGET : achieve leadership position on our markets in Europe and Asia as of 2026

Major Partnership signed in 09/22 with Hansoh Pharmaceuticals for the distribution of KiOmedine®^{Vs}One in China, representing a potential of 66M € in milestones and 300M € in revenues

Osteoarthritis
✓ Further grow Europe and Asia market presence of KiOmedine®^{Vs}One
✓ Launch in China in partnership with Hansoh Pharmaceuticals
✓ Launch of new range of innovative solutions

Aesthetic medicine
✓ CE Mark of our skin booster ('24)
✓ CE mark of our range of 3 dermal fillers ('25-'26)

Ophthalmology
✓ Development of eye drops for dry eyes

In Our Portfolio

info@wishbone-biotech.com
www.wishbone-biotech.com

Corporate

2013 – Certech and The Faktory
2011 - €2,7M investment round
2022 -€1M non-dilutive funding
Daniel BEE – CEO
Emilie DORY - COO
Eric ROMPEN - Founder

Technology

Development of superior bone graft substitute products for dental reconstruction surgery.

Wishbone has pioneered a breakthrough technology and innovative processes to develop a pipeline of new products for dental surgery building on its advanced bone graft material.

Business

Enhanced version of the current advanced xenograft product ready for clinical study
- Exceptional results from the pre-clinical study

USA distribution partnership
- Building a KOL network of clinician users

Milestones

2021 – USA regulatory clearance
2022 - USA Commercialisation, first patients and appointment of distribution partner

In Our Portfolio

nancy.vanoverstraeten@spinovit.com
www.spinovit.com

Corporate

SPINOVIT is a spin-off from UCLouvain originated from Prof. JL Baligand's lab. It was created in February 2022.
The founder is Nancy Van Overstraeten.
The investing partners are Sopartec, SRIW and B2start.

Technology

SPINOVIT proposes a solution to detect the earliest stages of a cardiovascular disease. The assessment of a robust biomarker of endothelial dysfunction allows the identification of the personal risk of a patient and so the prevention of the development of a cardiovascular disease.

Business

Our beachhead market are the anesthesiologists. We are finishing a pivotal clinical study (POC) demonstrating the superiority of our biomarker HbNO in the stratification of patients at risk to develop perioperative cardiovascular complications.

Milestones

We will finish our clinical study during summer 2023.
Preliminary results in January 2023 will allow the preparation of the next funding round expected for September 2023.
The next steps will involve confirmatory clinical studies, launch on the market and submission of the IVDR certification.

In Our Portfolio

neuroClues
biomarkers in a blink

Antoine.pouppez@p3lab.com
www.p3lab.com

Corporate

Mission
Our ambition with NeuroClues is to **become the brain's stethoscope.** Our mission is to empower clinicians with Biomarkers allowing them to identify Neurological Disorders (Parkinson's Disease, Alzheimer's Disease and Multiple Sclerosis) years before visible symptoms.

Funding
Current : 2,5M€ in Seed round/4.7M€ in DGO6 and EIC support
Seeking in H3 2023 : 4M€ from TIER 1 VC +10M€ in Q3 2024

Origin
Belgium (LLN) in July 2020

Business

Our Target Market Size by 2030 is 9 000 devices in leading to an ARR of 76M€ with 260 000 potential users (neurologists and vision specialists) worldwide leading to a Service Addressable Market of 1.5 bn€.
The total market size for neurological biomarkers in the clinical practice is 2 300 000 Clinical practitioners.

The clinical act is already reimbursable in most EU countries (FR-60€) and US (100$) leading to a positive business case for practitioners.

Main competitors are North-American based startups and scaleups with recent product launch relying on third party hardware solutions. In Europe, competition is setting up in the medical sector, demonstrating increased market readiness.

Technology

NeuroCluesTM is a unique eye tracking solution integrating - a portable laboratory performing high quality measurements (800 fps) and analysis (with FPGA) within a controlled environment and in an ecological/comfortable patient position. - a frictionless software giving access to clinically relevant paradigms and providing science based biomarkers within minutes. - a series of services with an encyclopedia, a worldwide normalized cloud base dataset and SW updates & HW upgrades.

Milestones

Next R&D steps to reach:
- V1 of Product ready
- EU : CE marking submission
- US: 510K FDA submission

Next commercial steps to reach:
- Public presentation at fairs and symposiums
- Secure Key Opinion Leaders as first users and early enthusiasts

Corporate objectives:
- Raise Serie A round

Board

Olivier Legrain (Chairman)
CEO at IBA

Marie Vidailhet
Head of Neurology at
La PitiéSalpêtrière hospital

Wallonie Entreprendre Life Sciences

In Our Portfolio

OSIMIS
IMAGING · RE-WIRED

Contact Person: Frederic Lambrechts
fla@osimis.io
www.osimis.io

Corporate

Founded in 2015
Fund raising in March 2019
Turnover 2018 : 480 k€
Actual team : 15 people

Technology

Medical imaging
Making image management and sharing in healthcare and other sectors simple, powerful and cost efficient through the use of open source software

Business

Several ongoing R&D programs
Current market targets: Belgium/Europe/US

Milestones

Significative growth of the turnover every year
Extend presence abroad
Team up to 20 people by end of 2020

In Our Portfolio

LiveDrop

Stephanie.vanloo@livedrop-bio.com
www. Livedrop-bio.com

Corporate

Spin-off from University of Liege, founded in 2022
Seed funding : 1,4 M€ + 0,9 M€ non dilutive
Team of 6 employees + freelancers
Stéphanie van Loo, CEO/CTO
Geoffrey Holsbeek, CBDO
Yacine Bounab, CSO

Technology

ModaFlow is an all-in-one integrated instrument based on droplet microfluidics for high-throughput single-cell screening and sorting.
ModaFlow is particularly adapted to single-cell analysis and sorting of fragile cells. Moreover, it allows unique secretome-based single-cell sorting, e.g. for the selection of monoclonal antibodies producing cells.

Business

Current market targets : institutional and private R&D laboratories, R&D department of biotech and biopharma companies active in the field of immunology, immuno-oncology, immunotherapy , bioproduction, microbiology, cell & gene therapy, regenerative medicine.

Milestones

Commercialisation of the first ModaFlow in 2023.

In Our Portfolio

Contact person: Jonathan Baut, CEO
jonathan.baut@gabismartcare.com
https://gabismartcare.com/

Corporate

Belgian MedTech startup
Founded in 2017 by Jonathan Baut (CEO) and Edouard Carton (COO)
Team of 15 employees and freelancers
4,8M€ raised since its inception

Technology

Gabi SmartCare develops the very first Smart Digital Health Platform solution dedicated to **Pediatrics** (0 to 12 years, including premature babies). By monitoring the child's main vital signs and interpreting them with AI (Artificial Intelligence), our solution allows the early **diagnosis**, daily management of various pathologies and **prevention** of events. The solution consists of a proprietary hardware and software components as well as a medical support service: the Gabi Band, the Gabi Monitor, the Gabi Analytics, and the Gabi Virtual Care Team.

Business

- **GEN 2** finalised and medically validated, **FDA Pre-sub** done, ongoing **clinical trials** (US and Belgium)
- Validated business model with a **2-step market penetration:** Direct-to-consumer approach, 0-2yrs old with a medical offering (Medical grade monitoring and Virtual care team empowered by the analytic platform). Generate health economics on that population to transition to private payers.
- Market geography: **US and EU**
- Top-notched **scientific and strategic board**

Milestones

Next years' main milestones:

- **Medical certification** in the US and EU by Q4 2023
- **Sales launch** (D2C sales) by Q1 2024
- **Certification** of the AI-based medical interpretation by the end of 2023

In Our Portfolio

Andre.claes@cerhum.com
www. cerhum.com

Corporate

Founded in 2016, spin out from Sirris
Fund raising since inception : 1,9m Euros
Headcount: 9
André Claes, CEO
Grégory Nolens, CSO
Thibaut Breuls de Tiecken, CFO

Technology

- **MyBone®** - 3D advanced bone graft solution for faster bone reconstruction (patented), with two EU commercialized products:
  - **MyBone® Custom**: Patient specific bone graft
  - **MyBone® CDMO**: Custom production as a subcontractor
- Medical 3D printing platform, ISO13485-2016 certified

Business

CERHUM is the leader in 3D printing synthetic bone graft.

- Superior solution in bone reconstruction with **MyBone®**
- Active in Maxillofacial, Plastic, Orthopedic and Spine surgery
- Commercially represented in five EU countries
- >10,000 bone graft/year production capacity

Milestones

Two years plan (2022-2024)

- Five folds increased number of sales with **MyBone® Custom**
- Triple the number of industrial partnership with **MyBone® CDMO**
- Double the number of Clinical partners to improve MyBone
- Obtain our first **FDA approval** (US market)
- Validate **MyBone®** to be used in intraoral and oncology indications.

In Our Portfolio

AXINESIS
ADVANCING REHABILITATION

pieter.vandensteen@axinesis.com
www. axinesis.com

Corporate

Spin-off UCLouvain, founded in 2015
Fund raising 3M€ since inception
Management team: Pieter Van den Steen (CEO) and Julien Sapin (Founder/CTO)

Technology

Area of interest: offering Intensive Functional Neurorehabilitation across the continuum of care
Products description: Portfolio for upper-limb neurorehabilitation, with an end-effector robotic device (REAplan), a functional virtual reality workstation (REAtouch) and a functional virtual reality workstation for decentralized therapy (REAtouch Lite)
Milestones: all three products are CE marked and commercially available in Europe

Business

- Realizing full commercial coverage of Europe, Canada and Australia
- R&D axes: Telerehabilitation and cognitive decline

Milestones

- 2022: Break-even
- 2023-2025: commercialization in US, China & Russia and launch of telerehabilitation and cognitive decline applications

Wallonie Entreprendre Life Sciences

In Our Portfolio

info@aardexgroup.com
www. aardexgroup.com

Corporate

Founded in 2015
Location: BE, CH, US
Funds raised: 6 Moi€
Headcount 2021: 24
David DALLA VECCHIA (Ir), CEO
Bernard VRIJENS (PhD), CEO

Business

AARDEX Group is the world leader in digital solutions to manage medication adherence in clinical trials.

- 70+ validated algorithms
- 830+ peer reviewed papers
- 1000+ clinical research studies
- 200+ phase II, III, IV drug trials
- 1.000.000+ patients monitored
- Active in 70+ countries

Technology

- **MEMS® Adherence Software**: powerful visualization and analytical tools supporting adherence-enhancing interventions
- **MEMS® Adherence Hardware**: ecosystem of connected packages & devices developed by AARDEX or qualified partners
- Compliant with medical regulations, CE labeling, FDA, GxP, ISO
- Registered Trademarks & Patented Technology

Milestones

A 3Y growth plan (2022 - 2024)

- A five-fold increase in the revenues
- A doubling of the team
- Extension of the connected packages/devices ecosystem
- Partnership with CMOs, CROs, and Software solutions used in Clinical Trials

In Our Portfolio

Contact: Michel Vanbrabant (CEO) -
info@istarmed.com
www.istarmed.com

Corporate

Founded in 2010 with exclusive IP rights to STAR® material for Ophthalmology, developed at University of Washington, USA

HQ in Wavre, Belgium.

FTE: 40+

Financing: Series A,B,C in 2013, 2016, 2019. Total raised ~115M€*.

CEO: Michel Vanbrabant

Business

Objective to be a best-in-class MIGS device for treatment of Glaucoma.

Strategic Alliance with AbbVie

- AbbVie will hold the exclusive right to acquire iSTAR Medical with additional contingent payments of up to $475M.

Clinical Results

- STAR-I,II,III pooled trial results @ 2Y for MINIject® show ~40% sustained reduction of pressure, with ~40 % patients free of pressure-lowering medication.

CE Mark

- Obtained in 2021. Commercial launch in select EU countries

FDA approval

- US IDE study granted approval by FDA to begin in 2021

Technology

Implants to treat Glaucoma
with innovative, soft, flexible, anti-fibrotic STAR® material, made of biocompatible, medical-grade silicone, which enables bio-integration of surrounding tissues into the material.

MINIject® micro-invasive glaucoma surgery (MIGS) device
designed to reduce pressure in front of eye caused by fluid build-up, in order to prevent damage to optic nerve. It does this by redirecting excess fluid to a natural drainage pathway (supraciliary outflow).

Milestones

2021:

- CE-Mark approval
- EU Commercial Launch
- US IDE approval by FDA

> 2021

- Strategic Alliance with AbbVie
- Commercial Launch in non-EU territories as from 2023
- US Commercial Launch expected in 2025/2026.

Wallonie Entreprendre Life Sciences

* incl. a 60m$ upfront payment received under the alliance with AbbVie

In Our Portfolio

Olivier Delporte, CEO:
odelporte@miracormedical.com
www.miracormedical.com

Corporate

Origin: Austria
Fund raising since inception: €65m equity
Management team: Olivier Delporte (CEO), Bertrand Grimmonpré (CFO)

Technology

Area of interest: Medical Device Company focused on Heart Failure prevention
Products description: PiCSO® Impulse System (Proprietary Console and catheter)
Milestones/POC reached:
Safety and efficacy demonstrated in +200 clinical studies. EU Randomized study underway.

Business

Current R&D programs:
RCT ongoing in #144 patients / #7 sites + development of console and catheter scalability.
EU: CE Mark: Obtained in June 2020
Current market targets:
Heart attacks, specifically anterior STEMIs (Available Market: >$8b)

Milestones

Next R&D /commercial steps to reach:
- US: IDE study approval by FDA
- Product ready for large production

Corporate objectives:
- Ensure company long-term financing
- Make PICSO leading therapy for infarct size reduction for heart attacks patients

In Our Portfolio

InvestorRelations@mithra.com
www.mithra.com

Corporate

Founded in 1999
Listed on Euronext since 2015 (MITRA)
David Horn Solomon, CEO | Christophe Maréchal, CFO

Corporate strategy

1) leverage the full potential of the E4 platform and explore other opportunities in healthcare, and
2) develop partnering for our CDMO technology platform (development and manufacturing)

Business

- Transforming Women's Health through innovation
- Developing products offering better efficacy, safety and convenience, meeting women's needs throughout their life span, with a focus on contraception and menopause
- Explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond
- Developing and manufacturing complex therapeutics

Technology

- Estetrol (E4), Mithra's unique native estrogen with a superior benefit/risk profile
- Expertise in development of complex and innovative long-acting polymeric forms and in fill & finish of biologics
- Mithra CDMO, industry partner with specialist development and manufacturing capabilities for innovative biologic injectables

Milestones

- **Donesta®**
  - Positive Phase 3 efficacy results
  - Promising topline safety results from Phase 3 Study in North America announced on 3 March 2023
  - Primary safety results from Phase 3 Study for Europe anticipated in H1 2024
  - European commercial partnership end 2022
- **Estelle®**: Commercialization worldwide since mid 2021 in most countries of Europe, US and UK (2022)
- **Myring®**: Commercialization worldwide, includin since January 2023

In Our Portfolio

Contact Person: Michel Detheux,
michel.detheux@iteostherapeutics.com
www.iteostherapeutics.com

Corporate

Spin off of Ludwig Cancer Research and de Duve Institute founded in 2011

$407M capital + €33M non dilutive funding

Listed on Nasdaq: ITOS

Headquarters in Watertown, MA + R&D in Gosselies, Belgium

M Detheux, CEO; J Lager, CMO; M Call, COO; M Gall, CFO, Y McGrath, CSO

Business

- In 2021, collaborated with GSK for EOS-448 program. iTeos received $625MM upfront with potential to receive up to $1.45B in milestone payments.
- iTeos and GSK are advancing various novel combinations in multiple trials with potential next generation immuno-oncology agents.
- Inupadenant advancing into multiple combination trials based on clinical data observed to date.
- Developing a sustainable pipeline with intra-portfolio synergies to accelerate and expand clinical development of our targets.
- Cash balance of ~$792MM as of Q2'22 providing a runway in to 2026 to support our clinical development plans for all programs.

Technology

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. The Company's innovative pipeline includes EOS-448, a high affinity, potent, anti-TIGIT antibody with a functional Fc domain and inupadenant, a next-generation adenosine A_{2A} receptor antagonist tailored to overcome cancer immunosuppression.

Milestones

- In collaboration w/ GSK, initiated randomized Ph2 trial in 1L NSCLC patients in combo with TIGIT + Jemperli (GSK's anti-PD1) in Q4'22.
- iTeos initiated a randomized Ph2 trial in 2L NSCLC patients with the combination of inupadenat + chemo in Q3'22.
- iTeos anticipates entering the clinic in 2023 with a first-in-class candidate targeting a new mechanism in the adenosine pathway.

In Our Portfolio

info@nyxoah.com
GenioSleep.com

Corporate

Founded in 2009
Global company with headquarter in Belgium and subsidiaries in Israel, Australia and USA
Olivier Taelman, CEO / Loïc Moreau, CFO
Dual listing on EURONEXT Brussels and NASDAQ

- **€85M ($100M) IPO on Euronext in Sept. 2020**
- **$97,8M IPO on NASDAQ in July 2021**

Member of Euronext Tech Leaders initiative & part of Euronext Tech Leaders Index

Business

1 Billion OSA sufferers worldwide
Target population: patients with moderate to severe OSA who have failed conventional PAP therapy
1M+ new eligible patients every year (500K in the US – 500K+ in Europe)
€20 Billion annual total addressable market

Technology

Medical technology focusing on Obstructive Sleep Apnea (OSA) therapy – the most common sleep disordered breathing condition
First and only leadless, battery-free bilateral neurostimulator – Single incision procedure and patient-centric solution
1.5T and 3T full-body MRI compatibility

Milestones

CE Mark in 2019

- Germany reimbursement and commercialization since 2020
- Switzerland funding and commercialization since 2021

Completion of BETTER SLEEP study leading to +30% therapeutic indications extension in Europe, unique to Nyxoah
Ongoing US IDE pivotal DREAM study for FDA approval
Ongoing ACCCESS IDE study for FDA CCC labelling expansion
Next Generation Genio 2.1 CE mark approved in Europe + FDA approved as part of ongoing DREAM and ACCCESS IDE studies

In Our Portfolio

Celyad Oncology

investors@celyad.com
www. celyad.com

Corporate

- **Founded in 2007**
- **Listed on Nasdaq & Euronext (CYAD)**
- **12 foundational U.S. patents associated with allogeneic CAR T for the treatment of cancer**
- **Michel Lussier, interim CEO | Charles Morris, CMO | Philippe Dechamps, CLO**

Technology

Developing non-gene edited approaches to allogeneic CAR T therapies for hematological malignancies and solid tumors.

- shRNA (short hairpin RNA) modulates gene expression without the need for gene editing
- TIM (TCR inhibitory molecule) interferes with the ability of the T cell receptor to signal
- Armored CAR franchise that engineers allogeneic CAR Ts with specific cytokines

'All-in-One' Vector approach streamlines process development and manufacturing while broadening the potential applicability of our candidates.

Business

- **Leveraging a Differentiated Approach to Allogeneic CAR Ts:** All-in-One vector approach combined with our proprietary non gene edited technologies (shRNA and TIM) and armored CAR franchise broadens potential applicability of candidates
- **shRNA platform for allogeneic CAR Ts:** Provides real world benefits of our approach to allogeneic CAR T with shorter manufacturing time, lower cost of goods sold and optimizing therapy with gene knockdown

Milestones

- **CYAD-211 in r/r MM:** Enrollment in the cohorts evaluating enhanced lymphodepletion is ongoing in the CYAD-211 IMMUNICY-1 trial and additional data from the trial are expected in the second half of 2022

Ready for (ad)venture capital funding?

We are on a mission to turn the Walloon region into a leading biotech hub in Europe—and a major player in the global life sciences landscape.

Get in touch on LinkedIn

@

WE Life Sciences

Wallonie Entreprendre Life Sciences